Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

CRMD

CorMedix Inc

Jan 14 • 04:00PM ET

7.09

+0.03 0.42 %

Healthcare • Biotechnology • USA • NASD

Peers: BCRX ADMA ANIP CTSO RMTI AMRX CRVS CLSD XTNT NAII

| Held by: VTI IWM VXF IWO VTWO SCHA XPH SFLO VHT CALF

Scroll to Statements

Index	RUT	P/E	3.45	EPS (ttm)	2.05	Insider Own	12.10%	Shs Outstand	78.35M	Perf Week	-36.53%
Market Cap	558.61M	Forward P/E	3.95	EPS next Y	1.79	Insider Trans	-3.70%	Shs Float	69.26M	Perf Month	-38.29%
Enterprise Value	507.28M	PEG	-	EPS next Q	0.84	Inst Own	56.67%	Short Float	24.11%	Perf Quarter	-32.73%
Income	162.50M	P/S	2.61	EPS this Y	1006.19%	Inst Trans	13.26%	Short Ratio	5.08	Perf Half Y	-36.30%
Sales	214.30M	P/B	1.48	EPS next Y	-34.00%	ROA	39.23%	Short Interest	16.70M	Perf YTD	-39.04%
Book/sh	4.78	P/C	10.03	EPS next 5Y	-	ROE	75.08%	52W High	17.43 -59.32%	Perf Year	-36.24%
Cash/sh	0.71	P/FCF	7.51	EPS past 3/5Y	25.91% 29.80%	ROIC	43.09%	52W Low	5.60 26.61%	Perf 3Y	59.68%
Dividend Est.	-	EV/EBITDA	4.69	Sales past 3/5Y	510.62% 173.65%	Gross Margin	92.61%	Volatility	11.12% 6.21%	Perf 5Y	-12.90%
Dividend TTM	-	EV/Sales	2.37	EPS Y/Y TTM	381.63%	Oper. Margin	48.51%	ATR (14)	0.75	Perf 10Y	-18.97%
Dividend Ex-Date	-	Quick Ratio	1.73	Sales Y/Y TTM	1647.67%	Profit Margin	75.83%	RSI (14)	23.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.94	EPS Q/Q	2767.80%	SMA20	-34.35%	Beta	1.37	Target Price	16.86
Payout	-	Debt/Eq	0.01	Sales Q/Q	810.22%	SMA50	-33.86%	Rel Volume	1.06	Prev Close	7.06
Employees	65	LT Debt/Eq	0.01	Earnings	Nov 12 BMO	SMA200	-37.12%	Avg Volume	3.29M	Price	7.09
IPO	May 13, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	98.64% 21.25%	Trades		Volume	3,487,084	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy	$14
Jun-30-25	Initiated	H.C. Wainwright	Buy	$20
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Mar-07-25	Initiated	Leerink Partners	Outperform	$18
Jan-13-25	Initiated	D. Boral Capital	Buy	$15
Aug-26-24	Initiated	Rodman & Renshaw	Buy	$13
Aug-10-23	Initiated	RBC Capital Mkts	Outperform	$6
Feb-17-21	Initiated	Needham	Buy	$31
Sep-29-20	Initiated	JMP Securities	Mkt Outperform	$22
Sep-21-20	Initiated	Truist	Buy	$20
Dec-18-19	Initiated	B. Riley FBR	Buy	$48
Mar-26-19	Reiterated	H.C. Wainwright	Buy	$3 → $15
Dec-06-18	Initiated	ROTH Capital	Buy	$6
Sep-25-17	Reiterated	H.C. Wainwright	Buy	$3 → $4
Aug-10-17	Reiterated	Rodman & Renshaw	Buy	$5 → $3
May-05-17	Reiterated	Rodman & Renshaw	Buy	$6 → $5
Nov-11-16	Reiterated	FBR & Co.	Outperform	$6 → $4
Mar-17-16	Reiterated	FBR Capital	Outperform	$7 → $6
Mar-03-16	Initiated	FBR Capital	Outperform	$7
Nov-16-15	Reiterated	ROTH Capital	Neutral	$2.75 → $2.50

Show Previous Ratings

Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks) -6.29%
11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
09:32AM	Loading…
09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
09:40AM	Are Investors Undervaluing CorMedix (CRMD) Right Now? (Zacks)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
08:30AM	CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks) -32.77%
12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks)
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
08:05AM	Loading…
08:05AM	CorMedix Therapeutics Announces Leadership and Board Updates (GlobeNewswire)
08:00AM	CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates (GlobeNewswire)
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks)
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks) -7.63%
11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks)
10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
10:54AM	Loading…
10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks) -6.81%
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
07:36AM	VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
Dec-30-25 11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-26-25 09:12AM	Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? (Zacks)
Dec-24-25 11:22AM	FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug (Zacks)
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
Dec-23-25 03:20PM	Why CorMedix Could be the Biopharma Name to Watch Early in 2026 (MarketBeat)
10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)
09:29AM	Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up (Zacks)
Dec-19-25 12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
10:10AM	MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab (Zacks)
08:59AM	Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema (Zacks)
Dec-18-25 10:51AM	SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag (Zacks)
09:21AM	PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study (Zacks)
08:00AM	CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath (GlobeNewswire)
07:59AM	INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset (Zacks)
Dec-17-25 11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
10:29AM	GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment (Zacks)
09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
Dec-16-25 10:43AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Zacks)
10:41AM	SNY Stock Down on Double Trouble With Multiple Sclerosis Drug (Zacks)
10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks)
09:55AM	CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike (Zacks)
08:53AM	GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal (Zacks)
07:04AM	5 High Earnings Yield Value Picks Ahead of Key Economic Reports (Zacks)
Dec-15-25 10:49AM	FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer (Zacks)
10:27AM	GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU (Zacks)
09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-12-25 10:08AM	GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea (Zacks)
Dec-11-25 11:03AM	GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer (Zacks)
10:57AM	CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? (Zacks)
10:30AM	Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III (Zacks)
Dec-09-25 10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
09:55AM	Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-08-25 12:00PM	CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +6.63%
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
07:19AM	Best Value Stocks to Buy for December 8th (Zacks)
05:30AM	New Strong Buy Stocks for December 8th (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
09:23AM	Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? (Zacks)
Dec-04-25 10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 12:41PM	Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case (Zacks) +5.52%
10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
Dec-02-25 02:21PM	REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD (Zacks)
02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUNTON ALAN W	Director	Dec 30 '25	Option Exercise	4.03	20,000	80,600	60,250	Jan 02 09:30 PM
DUNTON ALAN W	Director	Dec 30 '25	Sale	13.00	20,000	260,000	40,250	Jan 02 09:30 PM
Alan Dunton	Director	Dec 30 '25	Proposed Sale	12.97	20,000	259,400		Dec 30 04:28 PM
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Option Exercise	4.43	30,000	132,900	539,496	Dec 19 09:30 PM
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Sale	12.00	30,000	360,000	509,496	Dec 19 09:30 PM
Joseph Todisco	Officer	Dec 18 '25	Proposed Sale	11.97	30,000	359,149		Dec 18 04:35 PM
Dillione Janet	Director	Dec 09 '25	Option Exercise	7.82	34,000	265,900	82,473	Dec 11 08:38 AM
Dillione Janet	Director	Dec 09 '25	Sale	12.00	34,000	408,000	48,473	Dec 11 08:38 AM
Lefkowitz Steven W	Director	Dec 09 '25	Sale	11.88	40,000	475,200	80,498	Dec 10 09:38 PM
Janet Dillione	BOD	Dec 09 '25	Proposed Sale	12.00	34,000	408,000		Dec 09 04:43 PM
Lefkowitz Steven W	Director	Dec 09 '25	Proposed Sale	11.26	40,000	450,400		Dec 09 04:27 PM
Dillione Janet	Director	Dec 02 '25	Option Exercise	3.96	46,657	184,802	95,130	Dec 04 09:30 PM
Dillione Janet	Director	Dec 02 '25	Sale	10.00	46,657	466,570	48,473	Dec 04 09:30 PM
Dillione Janet	Director	Nov 24 '25	Option Exercise	3.64	26,343	95,948	74,816	Nov 26 09:30 PM
Dillione Janet	Director	Nov 24 '25	Sale	9.93	26,343	261,586	48,473	Nov 26 09:30 PM
Janet Dillione	Director	Nov 24 '25	Proposed Sale	9.97	73,000	727,927		Nov 24 04:14 PM
Dillione Janet	Director	Nov 14 '25	Sale	11.42	30,000	342,600	48,473	Nov 18 09:45 PM
Dillione Janet	Director	Nov 14 '25	Proposed Sale	10.94	30,000	328,200		Nov 14 12:54 PM
Erin Mistry	Former Officer	Nov 10 '25	Proposed Sale	10.98	13,543	148,719		Nov 10 05:10 PM
Erin Mistry	Former Officer	Nov 06 '25	Proposed Sale	10.97	13,908	152,503		Nov 06 04:27 PM
Kaplan Myron	Director	Oct 23 '25	Buy	11.02	25,000	275,500	201,034	Oct 27 09:30 PM
Duncan Gregory Scott	Director	Sep 16 '25	Option Exercise	8.32	13,333	110,931	38,333	Sep 18 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Option Exercise	3.55	10,000	35,500	50,250	Sep 16 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Sale	13.13	10,000	131,300	40,250	Sep 16 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Option Exercise	3.47	50,000	173,500	559,496	Sep 12 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Sale	13.00	50,000	650,000	509,496	Sep 12 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Proposed Sale	13.10	10,000	130,950		Sep 12 04:37 PM
Todisco Joseph	Officer	Sep 12 '25	Proposed Sale	12.97	50,000	648,569		Sep 12 04:31 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Option Exercise	3.30	50,000	165,000	230,418	Sep 11 09:45 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Sale	13.41	50,000	670,264	180,418	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Option Exercise	1.45	41,121	59,625	218,111	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Option Exercise	1.45	12,876	18,670	189,866	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Sale	13.08	41,121	537,863	176,990	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Sale	13.51	12,876	173,955	176,990	Sep 11 09:45 PM
Zelnick Kaufman Beth	Officer	Sep 09 '25	Proposed Sale	13.46	50,000	673,000		Sep 09 04:52 PM
Hurlburt Elizabeth	Officer	Sep 09 '25	Proposed Sale	13.50	53,997	728,959		Sep 09 04:51 PM
David Matthew T	Former Officer	Sep 03 '25	Proposed Sale	14.50	300,000	4,350,000		Sep 03 04:32 PM
Lefkowitz Steven W	Director	Apr 02 '25	Option Exercise	4.03	20,000	80,600	120,498	Apr 03 04:30 PM
Todisco Joseph	Chief Executive Officer	Apr 01 '25	Option Exercise	3.38	59,170	199,995	530,721	Apr 02 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRMD

CorMedix Inc

Upgrade your FINVIZ experience